Reviewing Edgewise Therapeutics (NASDAQ:EWTX) and Prestige Consumer Healthcare (NYSE:PBH)

Edgewise Therapeutics (NASDAQ:EWTX) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Risk and Volatility

Edgewise Therapeutics has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500.

Earnings and Valuation

This table compares Edgewise Therapeutics and Prestige Consumer Healthcare”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$100.16 million	($1.55)	-23.19
Prestige Consumer Healthcare	$1.13 billion	3.29	$209.34 million	$4.09	18.28

Prestige Consumer Healthcare has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. 24.1% of Edgewise Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Prestige Consumer Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Edgewise Therapeutics and Prestige Consumer Healthcare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-28.01%	-26.69%
Prestige Consumer Healthcare	18.43%	12.55%	6.11%

Analyst Recommendations

This is a breakdown of recent recommendations for Edgewise Therapeutics and Prestige Consumer Healthcare, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	0	0	5	0	3.00
Prestige Consumer Healthcare	0	2	3	0	2.60

Edgewise Therapeutics presently has a consensus target price of $35.60, indicating a potential downside of 0.95%. Prestige Consumer Healthcare has a consensus target price of $94.20, indicating a potential upside of 25.99%. Given Prestige Consumer Healthcare’s higher probable upside, analysts clearly believe Prestige Consumer Healthcare is more favorable than Edgewise Therapeutics.

Summary

Prestige Consumer Healthcare beats Edgewise Therapeutics on 10 of the 13 factors compared between the two stocks.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.